Three Cases of Verruca Plana Treated Successfully with 5% Imiquimod Cream

Hei Sung Kim, M.D., Hyun Jeong Park, M.D., Jun Young Lee, M.D., Baik Kee Cho, M.D.

Department of Dermatology, St. Mary's Hospital, College of Medicine,
The Catholic University of Korea, Seoul, Korea

Imiquimod is an immune-response modifier, currently approved by the FDA for topical treatment of external genital and perianal warts. Verruca plana (flat warts) is a common disease, which can cause substantial cosmetic problems. Three patients with verruca plana resistant to other therapies, including topical retinoic acid, were treated with 5% imiquimod cream. Complete resolution of the lesions occurred within a month of applying topical imiquimod cream. No serious side effects were observed after application of topical imiquimod cream. Due to the success of this treatment, we consider topical imiquimod cream to be a good treatment modality for verruca plana, especially in the cases resistant to conventional therapies. (Ann Dermatol 17(1) 38~40, 2005)

Key Words: Imiquimod, Verruca plana

INTRODUCTION

Imiquimod, an imidazoquinoline amine, is a new immune response modifier for local application and is currently approved as a treatment of choice for anogenital warts. Imiquimod exerts its action by stimulating the release of cytokines from local peripheral blood mononuclear cells and keratinocytes. Enhancement of Langerhans cell migration from skin to lymph nodes has been observed too.

Imiquimod might be effective on verruca plana, as the etiologic origin of anogenital warts and those of verruca plana are similar. The efficacy and safety of imiquimod has been demonstrated in patients with recalcitrant flat warts. Successful topical therapy of imiquimod on verruca plana has not been reported in Korea. Herein, the authors report three cases of verruca plana treated with 5% topical imiquimod cream, which has demonstrated excellent clinical results without serious side effects.

CASE REPORT

Case 1

Crops of flat warts with predilection to the area below the eyebrows, were observed on the face of a 19-year-old female over a 1 month period (Fig. 1A). The patient had a long history of inflammatory acne and had been under therapy with oral, topical isotretinoin, and chemical peeling. Histopathologically, hyperkeratosis, acanthosis and vacuolization of the cells in the granular layer were observed, and were found to be consistent with verruca plana (Fig. 2). 5% topical imiquimod cream was prescribed for application three times per week before bed. After 2 weeks of therapy the flat warts had almost cleared. The patient did not experience any pain, stinging, redness or edema at the treatment site. Complete clearing of all flat warts occurred after 4 weeks of therapy with 5% topical imiquimod cream (Fig. 1B).

Case 2

A 26-year-old female presented with a 3-year history of multiple papular lesions on both arms, which had not responded to immunotherapy with dinitrochlorobenzene (DNCB). There was no other
Verruca Plana Treated Successfully with 5% Imiquimod Cream

Fig. 1. (A) Flat warts at presentation. (B) Complete clearing of warts after 4 weeks of therapy.

Fig. 2. Compact hyperkeratosis with loss of basket-woven appearance in the stratum corneum is observed together with diffuse vacuolization of the cells in the upper stratum malphigii (Haematoxylin and eosin; original magnification ×400).

personal history to note. Initially, a daily application of 5% topical imiquimod cream was recommended. However, after a week of therapy, the patient complained of burning, erythema, crusting and scabbing of individual lesions, so the application of imiquimod cream was reduced to twice per week. Complete clearance of lesions occurred after 4 weeks of therapy. No other cutaneous or systemic side effects were observed during the rest of the treatment period.

Case 3
A 29-year-old male patient presented with an 8-month history of flat warts on the face. The patient had no specific past or family history. Histopathologic findings from a punch biopsy specimen were consistent with verruca plana. 5% imiquimod cream was prescribed for application to the face three times per week at bedtime. Marked improvement was noted after one week of therapy, and the lesions completely disappeared after five weeks. The patient did not experience pain or edema at the treatment site. However, erythema and post-inflammatory hyperpigmentation of the lesion site was observed after one week and five weeks of therapy, respectively. After the termination of imiquimod, hyperpigmentation gradually improved, with normalization of skin color within 3 months.

DISCUSSION

Flat warts are benign lesions that occur predominantly in younger patients. They usually disappear spontaneously, but occasionally are long lasting and thus require keratolytic therapy or cryotherapy, which may cause pain or residual scarring. Other treatments for flat warts, such as retinoic acid and immunootherapy with DNBCB have been employed. Unfortunately, retinoic acid can sometimes be ineffective and is often not tolerated due to irritation and photosensitivity. DNBC may cause allergic contact dermatitis and has been reported to be a carcinogen.

Imiquimod is an immune-response modifier. In 1997, it was approved by the FDA for the topical treatment of external genital and perianal warts in adults. Imiquimod enhances the body's immune response to HPV infection. Specifically, imiquimod stimulates local peripheral blood mononuclear cells and keratinocytes to secrete cytokines, including
Table 1. Reported Cases of Verruca Plana in Immunocompetent Patients Treated with Imiquimod

<table>
<thead>
<tr>
<th>Patient 1 5 (M/42)</th>
<th>Site of the lesion</th>
<th>Duration</th>
<th>Treatment outcome</th>
<th>Side effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Back of the hands, fingers and lower arms</td>
<td>2 years</td>
<td>Complete disappearance after 6 weeks</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Patient 2 6 (F/21)</td>
<td>Forehead</td>
<td>2 years</td>
<td>Complete disappearance after 2 weeks</td>
<td>Sore muscles Submental lymphadenopathy</td>
</tr>
<tr>
<td>Our case 1 (F/19)</td>
<td>Face</td>
<td>1 month</td>
<td>Complete disappearance after 4 weeks</td>
<td>None</td>
</tr>
<tr>
<td>Our case 2 (F/26)</td>
<td>Both arms</td>
<td>3 years</td>
<td>Complete disappearance after 4 weeks</td>
<td>Burning, erythema, crusting and scabbing of the lesions</td>
</tr>
<tr>
<td>Our case 3 (M/29)</td>
<td>Face</td>
<td>8 months</td>
<td>Complete disappearance after 5 weeks</td>
<td>Erythema, Hyperpigmentation</td>
</tr>
</tbody>
</table>

interferon-α, tumor necrosis factor and interleukins 1, 6 and 8. These cytokines stimulate local immune effects that are cytotoxic against HPV without causing the tissue destruction characteristic of other treatment methods.

The most common side effect of imiquimod is erythema at the treatment site. This was observed in the 29-year-old male patient after just one week of therapy, but it rapidly improved within a week. The patient also experienced residual hyperpigmentation, which gradually resolved within 3 months of terminating the treatment with imiquimod. Other less commonly experienced adverse effects include local erosions, flaking, scabbing, induration, and edema. Systemic side effects such as flu-like symptoms, headache, and myalgia may appear, but are rare.

Imiquimod represents a unique therapeutic agent in the armamentarium against cutaneous HPV infection. So far, 2 studies of topical imiquimod on flat warts in immunocompetent patients have been reported; one on the fingers and backs of the hands and the other on the face of an otherwise healthy female. Both had a favorable outcome. Overall, the treatment was found to be safe, non-irritating, easy-to-use, and resulted in an excellent cosmetic outcome in all 3 of our patients (Table 1). In terms of side effects, imiquimod caused some itching, burning, irritation and pain, but was well-tolerated and spontaneous resolution was observed shortly after application. In conclusion, we believe that imiquimod is a highly suitable method for treating flat warts, especially those on the face, as treatment can be self-administered by the patient.

REFERENCES